Evidence map›Paper›PMID 29080368›Full record

ArticleThe British journal of dermatology2018

Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.

L Thorlacius, A Garg, J R Ingram, B Villumsen, P Theut Riis, A B Gottlieb, J F Merola, R Dellavalle, C Ardon, R Baba and 30 more

Abstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Guideline
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Observational
  8. Observational
  9. Review
  10. Article
  11. Hidradenitis suppurativa.Nature reviews. Disease primers · 2020
    Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors.

L ThorlaciusDepartment of Dermatology, Zealand University Hospital, Roskilde, Health Sciences Faculty, University of Copenhagen, Denmark.ORCID 0000-0002-3734-9607
A GargDepartment of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, U.S.A.
J R IngramInstitute of Infection and Immunity, University Hospital of Wales, Heath Park, Cardiff, U.K.ORCID 0000-0002-5257-1142
B VillumsenPatient Representative, The Patients' Association HS Denmark, Denmark.
P Theut RiisDepartment of Dermatology, Zealand University Hospital, Roskilde, Health Sciences Faculty, University of Copenhagen, Denmark.ORCID 0000-0001-7723-8779
A B GottliebDepartment of Dermatology, New York Medical College, Valhalla, NY, U.S.A.
J F MerolaHarvard Medical School, Boston, MA, U.S.A.
R DellavalleDermatology Service, U.S. Department of Veteran Affairs Medical Centre, Denver, CO, U.S.A.
C ArdonDepartment of Dermatology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
R BabaFormer National Advisor to the Ministry of Health, Malaysia.
F G BecharaDepartment of Dermatologic Surgery, St Josef Hospital, Ruhr-University, Bochum, Germany.
A D CohenSiaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.ORCID 0000-0002-8377-9982
N DahamDepartment of Dermatology, Tufts Medical Center, Boston, MA, U.S.A.
M DavisDepartment of Dermatology, Mayo Clinic, Rochester, MN, 5590, U.S.A.
L EmtestamDepartment of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
P Fernández-PeñasDepartment of Dermatology, Westmead Hospital, Sydney Medical School, The University of Sydney, Sydney, Australia.
M FilippelliPatient Representative, Morgantown, WV, U.S.A.
A GibbonsPatient Representatives, The Hidradenitis Suppurativa Trust, Rochester, U.K.
T GrantPatient Representative, Tucson, AZ, U.S.A.
S GuilbaultPatient Representative, Hope for HS, Detroit, MI, U.S.A.
S GulliverDepartment of Research, Newlab Clinical Research, NL, Canada.
C HarrisPatient Representative, Cardiff, U.K.
C HarventPatient Representative, Patients' Association: La Maladie de Verneuil en Belgique, Erbisoeul, Belgium.
K HoustonPatient Representatives, The Hidradenitis Suppurativa Trust, Rochester, U.K.
J S KirbyDepartment of Dermatology, Penn State Hershey Medical Center, Hershey, PA, U.S.A.
L MatusiakDepartment of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland.
A MehdizadehDalla Lana School of Public Health, University of Toronto, ON, Canada.
T MojicaPatient Representative, Brick, NJ, U.S.A.
M OkunFort HealthCare, Fort Atkinson, WI, U.S.A.
D OrgillDivision of Plastic Surgery, Brigham and Women's Hospital, Boston, MA, U.S.A.
L PallackPatient Representative, Longmont, CO, U.S.A.
A Parks-MillerHope for HS, Detroit, MI, U.S.A.
E P PrensDermatology Service, U.S. Department of Veteran Affairs Medical Centre, Denver, CO, U.S.A.
S RandellPatient Representative, Hope for HS, Detroit, MI, U.S.A.
C RogersPatient Representative, HS Aware, Toronto, ON, Canada.
C F RosenDivision of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.
S E ChoonDepartment of Dermatology, Hospital Sultanah Aminah, Johor Bahru, Malaysia.
H H van der ZeeDermatology Service, U.S. Department of Veteran Affairs Medical Centre, Denver, CO, U.S.A.
R ChristensenMusculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, the Capital Region of Denmark, Copenhagen, Denmark.
G B E JemecDepartment of Dermatology, Zealand University Hospital, Roskilde, Health Sciences Faculty, University of Copenhagen, Denmark.

Funding

Development of Outcome Measures for Hidradenitis SuppurativaK08HS024585 · AHRQ · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KIRBY, JOSLYN S · 2016 to 2019
$633k
AHRQ HHS K08 HS024585HCRW_ HF-14-08NIAMS NIH HHS L30 AR072438
6 · The paper itself

Abstract

backgroundA core outcomes set (COS) is an agreed minimum set of outcomes that should be measured and reported in all clinical trials for a specific condition. Hidradenitis suppurativa (HS) has no agreed-upon COS. A central aspect in the COS development process is to identify a set of candidate outcome domains from a long list of items. Our long list had been developed from patient interviews, a systematic review of the literature and a healthcare professional survey, and initial votes had been cast in two e-Delphi surveys. In this manuscript, we describe two in-person consensus meetings of Delphi participants designed to ensure an inclusive approach to generation of domains from related items.

objectivesTo consider which items from a long list of candidate items to exclude and which to cluster into outcome domains.

methodsThe study used an international and multistakeholder approach, involving patients, dermatologists, surgeons, the pharmaceutical industry and medical regulators. The study format was a combination of formal presentations, small group work based on nominal group theory and a subsequent online confirmation survey.

resultsForty-one individuals from 13 countries and four continents participated. Nine items were excluded and there was consensus to propose seven domains: disease course, physical signs, HS-specific quality of life, satisfaction, symptoms, pain and global assessments.

conclusionsThe HISTORIC consensus meetings I and II will be followed by further e-Delphi rounds to finalize the core domain set, building on the work of the in-person consensus meetings.

Indexed as

Clinical Trials as TopicConsensusConsensus Statements as TopicDelphi TechniqueGlobal HealthHidradenitis SuppurativaHumansTreatment Outcome

Identifiers

PMID29080368
PMCPMC5935265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.